Hygia Reagents Inc buyer-window signal capture
Three programs funded this year to turn a bench process into clinical-grade material, in the modalities Hygia Reagents named: exosome, iPSC-derived cells, stem-cell-derived islets. Revised 8 September, replacing the three programs sent earlier.
01 The Tiny Cargo CompanyHigh confidence An NIH award that started on 2026-07-01 funds Tiny Cargo to establish GMP production of XoLacta, its milk exosome drug. In February 2026 it opened a Roanoke plant with over 2,000 square feet of cleanroom for exosome manufacturing. +View evidence, opening, contactHide details
Evidence
- NIH U44 award 1U44TR004958-01A1 to Tiny Cargo started 2026-07-01, runs to 2028-06-30, $985,974 in year one; its aims are industrial-scale lyophilization of XoLacta and establishing GMP production of XoLacta.
- On 2026-02-24 Tiny Cargo opened a $1.5 million Roanoke facility with over 2,000 square feet of cleanroom, described as among the first dedicated exosome manufacturing sites, creating six jobs.
Practical opening“An NIH award that started on 2026-07-01 funds Tiny Cargo to establish GMP production of XoLacta, its milk exosome drug. In February 2026 it opened a Roanoke plant with over 2,000 square feet of cleanroom for exosome manufacturing. That suggests those buffers are being specified now, by Tiny Cargo itself. We could ask what the first GMP campaign's buffers need and offer a lot-level CoA.”
Claim boundaryDo not say the first GMP lot is scheduled, that the plant is GMP certified, or that Tiny Cargo buys any material outside; the record shows a funded GMP build and its start date.
Roanoke, Virginia is 2,100 miles from San Diego, so proximity is not a wedge and qualification runs on documents and shipped samples.
Decision ownerDavid Whitt, Senior Manufacturing Manager · david.whitt@tinycargo.com, checked 2026-09-08 · cc Spencer Marsh, Chief Scientific Officer, spencer@tinycargo.com
02 Savanna BiotherapeuticsHigh confidence CIRM's board approved a $12,993,456 preclinical award to Savanna on 2025-12-11 and lists it as Active. CIRM's review says Savanna's first funded step is to finalize its manufacturing process at a university biomanufacturing center. +View evidence, opening, contactHide details
Evidence
- CIRM award PDEV-19149 to Savanna Biotherapeutics, PI Dr. Sunil Gandhi, $12,993,456, status Active, for microglia replacement therapy; the board approved it on 2025-12-11.
- CIRM's board review for PDEV-19149 records the applicant's first activity as finalizing the manufacturing process, and reviewers note the technology will be transferred to a university biomanufacturing center.
Practical opening“CIRM's board approved a $12,993,456 preclinical award to Savanna on 2025-12-11 and lists it as Active. CIRM's review says Savanna's first funded step is to finalize its manufacturing process at a university biomanufacturing center. That suggests the product's media and cryopreservation medium are being specified now. We could ask whether the center supplies the differentiation and cryo medium or Savanna sends its own.”
Claim boundaryDo not say Savanna is buying media or buffers, do not name the university center, and do not call the company small on headcount evidence we do not have.
The university biomanufacturing center may source qualified materials itself, leaving only the sponsor's proprietary medium and cryopreservation formulation open.
Decision ownerDr. Sunil Gandhi, Founding Chief Technology Officer; PI, CIRM PDEV-19149 · sunil.gandhi@savannabio.com, checked 2026-09-08 · cc Robert Spitale, Co-founder and CEO, robert.spitale@savannabio.com
03 EVADE TherapeuticsConditional causal link CIRM's board approved the $12,480,000 EVADE award on 2026-06-25. The CIRM review says EVADE's funded work includes finalizing GMP manufacturing, quality control and release for a cryopreserved product, starting from new cell banks. +View evidence, opening, contactHide details
Evidence
- On 2026-06-25 the CIRM board approved PDEV-19735, $12,480,000, to S. Schrepfer at EVADE Therapeutics, for hypoimmune stem cell-derived islets for type 1 diabetes.
- CIRM's board review for PDEV-19735 records the applicant's activity to finalize GMP manufacturing, quality control and release strategy for an IND-ready, cryopreserved product; reviewers say the grant funds the new master and working cell banks.
Practical opening“CIRM's board approved the $12,480,000 EVADE award on 2026-06-25. The CIRM review says EVADE's funded work includes finalizing GMP manufacturing, quality control and release for a cryopreserved product, starting from new cell banks. That suggests its stage-specific differentiation media and cryo medium are being chosen for the first time. We could ask whether the partner supplies those media and buffers or EVADE specifies its own.”
Claim boundaryDo not say work has started, do not guess the manufacturing partner, and do not treat the award as revenue: it is Pre-Active.
The manufacturing partner is redacted in the CIRM review and may be a commercial CDMO that supplies all materials.
Decision ownerSonja Schrepfer, Principal Investigator, CIRM PDEV-19735 (founder) · sonja.schrepfer@evade-tx.com, checked 2026-09-08
These signals rank research priority. They do not prove purchase intent. Every date and quote is from the public record; none of these companies has said it is buying media, buffers or cryopreservation medium.